



Fax completed form to Navitus at: 855-668-8553
For questions, please call: 877-908-6023

TEXAS MEDICAID

Drug Prior Authorization

Recurrent Vulvovaginal Candidiasis (RVVC) Agents

Request Information (required)

This request is:

- Expedited* (Urgent)
- Standard (Non-Urgent)

*Expedited means the standard review time may seriously harm the member's life, health, or ability to regain maximum function.

Member Information (required)

Prescriber Information (required)

Member Name:			Prescriber Name:		
Member Insurance ID #:			NPI # :		Specialty:
Date of Birth:			Office Phone:		
Member Phone:			Office Fax:		
Member Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:

Please fill out the following information:

- Medication Requested (Name):
(Go to #2)

2. Quantity Requested:
(Go to #3)

3. Dose Requested (Strength):
(Go to #4)

4. Dosing Instructions:
(Go to #5)

Required Criteria

5. Provide primary diagnosis including ICD-10 code(s):
(Go to #6)

6. Please indicate the requested drug's formulary status: *(Formulary available at www.txvendordrug.com)

Non-Preferred Drug (NPD or NAP)

(Go to #7)

Preferred Drug (PDL)

(Go to #10)

No Status, Drug is not in a Market Basket

(Go to #10)

N/A as this request is for a CHIP/PERINATE member

(Go to #10)

Preferred Drug List (PDL) Criteria (required for non-preferred products)

7. Has the member failed a 14-day treatment trial with at least one (1) preferred agent in the last 180 days?

Yes

(Go to #10)

No

(Go to #8)

8. Is there a documented allergy or contraindication to preferred agents in this class?

Yes

(Go to #10)

No

(Go to #9)

9. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?

Yes

(Go to #10)

No (Deny)

(Go to #10)

Clinical Criteria (required)

10. Is the member female?

Yes
(Go to #11)

No (Deny)
(Go to #11)

11. Is the member greater than or equal to (\geq) 52 years of age?

Yes
(Go to #13)

No
(Go to #12)

12. Does the member have a diagnosis that leads to permanent infertility (tubal ligation, hysterectomy, or salpingo-oophorectomy)?

Yes
(Go to #13)

No (Deny)
(Go to #13)

13. Does the member have a diagnosis of recurrent vulvovaginal candidiasis (greater than or equal to (\geq) three (3) acute vulvovaginal candidiasis [VVC] episodes in 12 months) in the last 365 days? [Manual]

Yes
(Go to #14)

No (Deny)
(Go to #14)

14. Has the member had a VVC recurrence during or after 180 days of oral fluconazole maintenance treatment, or does the member have a contraindication to oral fluconazole? [Manual]

Yes
(Go to #15)

No (Deny)
(Go to #15)

15. Does the member have a diagnosis of severe renal impairment or moderate to severe hepatic impairment in the last 365 days?

Yes (Deny)
(Go to #16)

No
(Go to #16)

16. Has the member had a treatment course (14 weeks) of oteseconazole (VIVJOA) in the last 365 days?

Yes (Deny)
(Go to #17)

No - Approve (14 weeks)
(Go to #17)

Additional Information

17. Please provide any additional information we should consider (or attach any supporting documents):
(END)

Submission Information (required)

Prescriber Signature: _____ Date: _____

**** PLEASE FAX COMPLETED FORM TO: 855-668-8553 ****

Drug Prior Authorization
Recurrent Vulvovaginal Candidiasis (RVVC) Agents

If criteria not met, submit chart documentation with form citing complex medical circumstances.
For questions, please call Customer Care at 877-908-6023

For questions, please call Navitus Customer Care at 1-877-908-6023.